HIV-positive women with cytomegalovirus, or CMV, in their urine at the time of labor and delivery are more than five times likelier than HIV-positive women without CMV to transmit HIV, the virus that causes AIDS, to their infants. The research also found that they are nearly 30 times likelier to transmit cytomegalovirus to their infants.
A new study has shown that boosting RV144 volunteers 6-8 years later with AIDSVAX B/E HIV vaccine resulted in higher immune responses than were seen immediately after RV144.
For decades, HIV has successfully evaded all efforts to create an effective vaccine but researchers at The Scripps Research Institute (TSRI) and the La Jolla Institute for Allergy and Immunology (LJI) are steadily inching closer. Their latest study, published in the current issue of Immunity, demonstrates that optimizing the mode and timing of vaccine delivery is crucial to inducing a protective immune response in a preclinical model.
As the HIV/AIDS epidemic approaches its fourth decade, each year brings promising news of pioneering research to alleviate the scourge. Add City College of New York scientists to the list with a rapid method to access new molecules that could inhibit the virus that causes AIDS.
The use of gift cards significantly increased viral suppression and clinic attendance among HIV-positive patients. Findings showed that there was a four-percent higher percentage of patients with viral suppression at HIV care sites that offered financial incentives at care sites compared to sites not offering gift cards. Additionally, there was an approximately 5 percent higher viral suppression noted among a subgroup of patients who previously had not shown consistent viral suppression.
Gift cards offered as financial incentives helped to increase viral suppression in human immunodeficiency virus (HIV)-positive patients in a community-based clinical trial in New York and Washington, D.C., two communities severely affected by HIV, according to a study published by JAMA Internal Medicine.
The HPTN 065 study, conducted by the HIV Prevention Trials Network (HPTN), showed that financial incentives can motivate some people living with HIV (PLWH) to take their HIV antiretroviral therapy (ART) medication regularly and maintain viral load suppression. This finding could have implications for improving health outcomes and decreasing the risk of transmitting the virus to others. Study findings were published today in JAMA Internal Medicine.
Study sheds new light on the mechanism underlying the persistence of HIV-1 infected cells despite antiviral treatment.
Understanding and responding to behavioral trends in groups that are at high risk for HIV infection is critical to the development of effective strategies that decrease HIV incidence and improve access to care. New research based on data from the Centers for Disease Control and Prevention's National HIV Behavioral Surveillance (NHBS) system are presented in a special supplement to JAIDS: Journal of Acquired Immune Deficiency Syndromes. The journal is published by Wolters Kluwer.
1 173 confirmed hepatitis A cases have been reported across 15 EU countries since June 2016. Several countries have seen increases in hepatitis A cases in 2017 compared to previous years, and these are mainly affecting men who have sex with men. In light of these outbreaks and the beginning of Pride period, ECDC stresses the importance of hepatitis A vaccination and the delivery of prevention messages as main options to avoid new infections.